Washington, DC - Diuretic therapy - commonly given to extremely preterm infants to help them overcome respiratory problems - appears to offer no benefit for this purpose, according to an analysis by researchers at the National Institutes of Health. Surprisingly, infants in the study who received diuretic therapy were more likely to require respiratory support, compared to extremely preterm infants with similar respiratory problems who did not receive the therapy. The study is published in The Journal of Pediatrics.

Washington, DC - The U.S. Food and Drug Administration granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). MRD refers to the presence of cancer cells below a level that can be seen under the microscope. In patients who have achieved remission after initial treatment for this type of ALL, the presence of MRD means they have an increased risk of relapse. 

Sacramento, California - California Attorney General Xavier Becerra expressed his strong opposition to the Department of Health and Human Services’ proposed regulations allowing healthcare providers to refuse to provide care based on religious or moral objections. The proposed regulations jeopardize crucial funding for California’s healthcare programs and would create barriers to access to care for women, LGBTQ individuals, and other Californians. 

Stanford, California - When a doctor or nurse suspects something is wrong with a patient’s heart, there’s a simple way to check: put a stethoscope over the heart and listen to the sounds it makes. Doctors and nurses can use the same diagnostic tool to figure out what’s going on with the heart, lungs, stomach and more, but not the brain – although that could change with a new device.

Washington, DC - The U.S. Food and Drug Administration today permitted marketing of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining blood glucose (sugar) levels in children aged two and older and adults with diabetes. This is the first type of continuous glucose monitoring system permitted by the agency to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Today’s authorization also classifies this new type of device in class II and subjects it to certain criteria called special controls. This enables developers of future iCGM systems to bring their products to market in the least burdensome manner possible.

Los Angeles, California - More than 29,000 women in California will be diagnosed with breast cancer in 2018. Many of them - especially low-income women, who suffer the worst survival rates — will face economic, emotional and structural obstacles to getting treatment and follow-up care.